BIT
CTMX icon

BlackRock Institutional Trust’s CytomX Therapeutics CTMX Stock Holding History

BlackRock Institutional Trust’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.24M Buy
203,920
+31,032
+18% +$376K ﹤0.01% 3014
2016
Q3 		$2.71M Buy
172,888
+7,264
+4% +$87.9K ﹤0.01% 2938
2016
Q2 		$1.69M Buy
165,624
+107,706
+186% +$1.23M ﹤0.01% 3100
2016
Q1 		$747K Buy
57,918
+25,477
+79% +$354K ﹤0.01% 3363
2015
Q4 		$677K Buy
+32,441
New +$513K ﹤0.01% 3431

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock Institutional Trust's CTMX Position: Q4 2016 in Review

BlackRock Institutional Trust increased its CytomX Therapeutics (CTMX) stake by 18% in Q4 2016, buying an estimated $376K and bringing the position to 203,920 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3014.

BlackRock Institutional Trust first reported a position in CTMX in Q4 2015 and has held it in 5 quarters since. The position peaked at $2.71M in Q3 2016. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

  • BlackRock Institutional Trust held 203,920 shares of CytomX Therapeutics worth $2.24M as of Q4 2016.
  • BlackRock Institutional Trust bought 31,032 CytomX Therapeutics shares in Q4 2016, an estimated $376K.
  • CytomX Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3014 holding.
  • BlackRock Institutional Trust first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • BlackRock Institutional Trust's CytomX Therapeutics position peaked at $2.71M in Q3 2016.
  • 68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.